title: Fibrate for treatment of primary biliary cirrhosis.
abstract: Recent studies of the effectiveness of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cirrhosis (PBC) reported that UDCA therapy did not necessarily stop the progression of liver fibrosis in all patients, even those with early stage PBC. Thus, there is a need for more effective treatments that could prevent asymptomatic PBC from progressing to the icteric stage. Bezafibrate is effective in approximately two-thirds of non-icteric patients who have not shown a complete response to UDCA. Serum bilirubin, aspartate aminotransferase and gamma-guanosine 5'-triphosphate levelswere significantly lower in patients who responded to additional bezafibrate on univariate analysis. The putative mechanism by which bezafibrate acts in cholestasis is by increasing phospholipid output into bile, which forms micelles with the hydrophobic bile acid that reduces its toxicity.
authors.affiliation: Department of Gastroenterology and Hepatology, Kochi Medical School, Nankoku, Kochi, Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Iwasaki
authors.forename: Naoaki
authors.initials: N
authors.lastname: Akisawa
authors.forename: Toshiji
authors.initials: T
authors.lastname: Saibara
authors.forename: Saburo
authors.initials: S
authors.lastname: Onishi